Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT02235519

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Hospital General de México Dr. Eduardo Liceaga (from the registry)
Registry
  • NCT NCT02235519
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02235519. Randomized; no masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
Condition
Hypertension
Condition
Obesity
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Azilsartan 40 mg.
Intervention (Drug)
Azilsartan 80 mg
Lead sponsor
Hospital General de México Dr. Eduardo Liceaga (class: other government)

Record details

Record id
cardio:ct-nct02235519
Content hash
c9fa6d1f47e4d470b10f474105c25023f0694804cbaa9ebc926521efbded8c22